WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, September 20, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT; THES=ASSIGNEE; PLUR=YES; OP=AND	
☐	L25	L22 (pulmonary or lung or respiratory)	17
☐	L24	L23 (pulmonary or lung or respiratory)	5
☐	L23	L19 (@py<2003)	5
☐	L22	L21 (@py<2003)	18
☐	L21	L18 and alpha adj1 lipoic	117
☐	L20	L19 alpha adj1 lipoic	5
☐	L19	L18 and L13	28
☐	L18	L16 or "CHRONIC BRONCHITIS" or "PULMONARY EMPHYSEMA"	16262
☐	L17	L16 or CHRONIC BRONCHITIS or PULMONARY EMPHYSEMA	20746
☐	L16	copd or "Chronic Airflow Obstruction" or "Airflow Obstruction" or "Chronic Obstructive Airway Disease" or "Chronic Obstructive Lung Disease" or "Chronic Obstructive Pulmonary Disease" or COAD	12857
☐	L15	L14 copd	3
☐	L14	L13 and alpha adj1 lipoic	95
☐	L13	silybin or Legalon or silymarin or silibinin	771
☐	L12	L10 and lung near obstructi$4	1
☐	L11	L10 and copd	2
☐	L10	silibinin and alpha adj1 lipoic	13
☐	L9	immune with (decrese$4 or suppress$4 inhib$5 or low$3 or block)	16115
☐	L8	acidi$9 with $5cell$5 with ph	2398
☐	L7	acidi$9 with $5cell$9 with ph	2414
☐	L6	L5 ph	0
☐	L5	L1 ($dissociat$6)	0
☐	L4	L1 ph ($dissociat$6)	0
☐	L3	L1 ph with ($dissociat$6)	0
☐	L2	L1 ph with (6.? or 7.$1)	0
☐	L1	6028098.pn.	1

END OF SEARCH HISTORY

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02  LMEDLINE coverage updated
 NEWS  3  JUL 02  SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02  CHEMCATS accession numbers revised
 NEWS  5  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  BEILSTEIN updated with new compounds
 NEWS 12  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 13  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 14  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 15  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 16  AUG 27  USPATOLD now available on STN
 NEWS 17  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 18  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 19  SEP 13  FORIS renamed to SOFIS
 NEWS 20  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 21  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 22  SEP 17  CAplus coverage extended to include traditional medicine
                  patents

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:21:21 ON 20 SEP 2007

=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:21:29 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3
DICTIONARY FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> e lipoic acid/cn
E1            1     LIPOHYDROPEROXIDASE/CN
E2            1     LIPOIC ACETYLTRANSFERASE/CN
E3            2 --> LIPOIC ACID/CN
E4            1     LIPOIC ACID ACETYLTRANSFERASE/CN
E5            1     LIPOIC ACID CHLORIDE/CN
E6            1     LIPOIC ACID DEHYDROGENASE/CN
E7            1     LIPOIC ACID DISULFONE/CN
E8            1     LIPOIC ACID FREE RADICAL/CN
E9            1     LIPOIC ACID METHYL ESTER/CN
E10           1     LIPOIC ACID SYNTHASE (ARABIDOPSIS THALIANA CLONE PRACE-5'/19
                    3K14/PBLUE-3' GENE LIP1 PRECURSOR)/CN
E11           1     LIPOIC ACID SYNTHASE (CAULOBACTER CRESCENTUS GENE CC1735)/CN
E12           1     LIPOIC ACID SYNTHASE (DEINOCOCCUS RADIODURANS STRAIN BAA-816
                     GENE DR0765)/CN

=> s e3
L1            2 "LIPOIC ACID"/CN

=> d

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   57828-26-9  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Lipoic acid  (CA INDEX NAME)
MF   Unspecified
CI   COM, MAN
LC   STN Files:   ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CASREACT, CIN, PROMT,
       SCISEARCH, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
             624 REFERENCES IN FILE CA (1907 TO DATE)
              30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             630 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d 1-2
```

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 57828-26-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN ***Lipoic acid*** (CA INDEX NAME)
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CASREACT, CIN, PROMT, SCISEARCH, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
624 REFERENCES IN FILE CA (1907 TO DATE)
30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
630 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 1200-22-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1,2-Dithiolane-3-pentanoic acid, (3R)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Dithiolane-3-pentanoic acid, (R)-
CN 1,2-Dithiolane-3-valeric acid, (+)- (8CI)
OTHER NAMES:
CN (R)-(+)-α-Lipoic acid
CN (R)-α-Lipoic acid
CN (R)-Lipoic acid
CN α-(+)-Lipoic acid
CN α-Lipoic acid
CN Byodinoral 300
CN d-Thioctic acid
CN Lipoec
CN ***Lipoic acid***
CN R-(+)-Thioctic acid
CN Thiogamma
CN Tiobec
CN Tiobec Retard
FS STEREOSEARCH
MF C8 H14 O2 S2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, EMBASE, IFICDB, IFIUDB, IMSDRUGNEWS, IMSRESEARCH, IPA, MRCK*, NAPRALERT, PROMT, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1993 REFERENCES IN FILE CA (1907 TO DATE)
90 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2013 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e silibinin/cn
E1            1     SILI 2401/CN
E2            1     SILI-HAFTLACK/CN
E3            1 --> SILIBININ/CN
E4            1     SILIBININ DIHEMISUCCINATE/CN
E5            1     SILIBOR/CN
E6            1     SILIBOR, COMPD. WITH B-CYCLODEXTRIN/CN
E7            1     SILIBRIN/CN
E8            1     SILIC Z 70/CN
E9            1     SILIC-SUPER H 80/CN
E10           1     SILICA/CN
E11           1     SILICA (28SIO2)/CN
E12           1     SILICA (29SIO2)/CN

=> s e3
L2            1 SILIBININ/CN

=> d


L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   22888-70-6  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   4H-1-Benzopyran-4-one, 2-[(2R,3R)-2,3-dihydro-3-(4-hydroxy-3-
     methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-
     trihydroxy-, (2R,3R)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1,4-Benzodioxin, 4H-1-benzopyran-4-one deriv.
CN   4-Chromanone, 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-
     (hydroxymethyl)-1,4-benzodioxan-6-yl]- (8CI)
CN   4H-1-Benzopyran-4-one, 2-[2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-
     (hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-,
     [2R-[2α,3β,6(2R*,3R*)]]-
CN   Silybin (7CI)
OTHER NAMES:
CN   7C3MT
CN   Silibinin
CN   Silliver
CN   Silybin A
CN   Silybin b1
CN   Silybine
CN   Silybum substance E6
CN   Silymarin I
CN   Silymarin MZ 80
CN   Silymarine I
FS   STEREOSEARCH
DR   11054-49-2, 11076-05-4, 11076-06-5, 22888-69-3, 50976-99-3, 37574-50-8,
     142796-20-1, 87725-90-4, 27359-03-1, 28577-40-4, 29832-10-8
MF   C25 H22 O10
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN,
       CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
       MRCK*, MSDS-OHS, NAPRALERT, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

798 REFERENCES IN FILE CA (1907 TO DATE)
38 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
802 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus, medline, uspatall

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.95	20.16

FILE 'CAPLUS' ENTERED AT 18:24:11 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:24:11 ON 20 SEP 2007

FILE 'USPATFULL' ENTERED AT 18:24:11 ON 20 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 18:24:11 ON 20 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:24:11 ON 20 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 and l2

L3	15	FILE CAPLUS
L4	0	FILE MEDLINE
L5	13	FILE USPATFULL
L6	0	FILE USPATOLD
L7	1	FILE USPAT2

TOTAL FOR ALL FILES
L8 29 L1 AND L2

=> s l8 and (copd or "Chronic Airflow Obstruction" or "Airflow Obstruction" or "Chronic Obstructive Airway Disease" or "Chronic Obstructive Lung Disease" or "Chronic Obstructive Pulmonary Disease" or COAD or "CHRONIC BRONCHITIS" or "PULMONARY EMPHYSEMA")

L9	1	FILE CAPLUS
L10	0	FILE MEDLINE

L11 0 FILE USPATFULL
L12 0 FILE USPATOLD
L13 0 FILE USPAT2

TOTAL FOR ALL FILES
L14 1 L8 AND (COPD OR "CHRONIC AIRFLOW OBSTRUCTION" OR "AIRFLOW OBSTRUCTION" OR "CHRONIC OBSTRUCTIVE AIRWAY DISEASE" OR "CHRONIC OBSTRUCTIVE LUNG DISEASE" OR "CHRONIC OBSTRUCTIVE PULMONARY DISEASE" OR COAD OR "CHRONIC BRONCHITIS" OR "PULMONARY EMPHYSEMA")

=> d scan

L14 1 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC ICM A61K031-366
ICS A61K031-20; A61K031-137; A61K045-06
CC 1-9 (Pharmacology)
TI Use of at least one effector of glutathione metabolism, together with α-lipoic acid, for the treatment of ***chronic obstructive lung diseases***
ST ***chronic obstructive lung disease***
treatment lipoate glutathione metab effector; cytoprotection
chronic obstructive lung disease
lipoate glutathione metab effector
IT Drug delivery systems
(aerosols; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Macrophage
(alveolar; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Lung, disease
(***chronic obstructive pulmonary disease***; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(emulsions; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Combination chemotherapy
Cytoprotective agents
Drug interactions
Human
Metabolism
Phagocytosis
(glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Thiols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(granules; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(inhalants; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)

IT Lung
(macrophage; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(oral; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(parenterals; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(powders; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(prodrugs; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(solns.; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(tablets, coated; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT Drug delivery systems
(tablets; glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT 70-18-8, Glutathione, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)
IT ***1200-22-2***, α-Lipoic acid 18683-91-5, Ambroxol
22888-70-6, Silibinin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glutathione metabolism effector with α-lipoic acid, for treatment of ***chronic obstructive lung disease***)

ALL ANSWERS HAVE BEEN SCANNED

=> s l8 and (lung or respirat? or pulmonar?)
L15 2 FILE CAPLUS
L16 0 FILE MEDLINE
L17 4 FILE USPATFULL
L18 0 FILE USPATOLD
L19 0 FILE USPAT2

TOTAL FOR ALL FILES
L20 6 L8 AND (LUNG OR RESPIRAT? OR PULMONAR?)

=> d scan

L20 6 ANSWERS USPATFULL
AN 2003:113490 USPATFULL

TI Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
NCL NCLM: 514/045.000
NCLS: 536/027.300
IC [7]
ICM A61K031-7076
ICS C07H019-16
IPCI A61K0031-7076 [ICM,7]; A61K0031-7042 [ICM,7,C*]; C07H0019-16 [ICS,7]; C07H0019-00 [ICS,7,C*]
IPCR C07H0019-00 [I,C*]; C07H0019-16 [I,A]
AN 2003:113490 DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L20 6 ANSWERS USPATFULL
AN 2007:164861 USPATFULL
TI Method of treating glutathione deficient mammals
NCL NCLM: 514/012.000
NCLS: 424/049.000; 424/054.000; 424/535.000; 424/655.000; 514/007.000; 514/021.000; 514/023.000; 514/251.000; 514/276.000; 530/365.000; 530/833.000
IC IPCI A01N0037-18 [I,A]; A61K0038-02 [I,A]
AN 2007:164861 DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L20 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC ICM A61K031-366
ICS A61K031-20; A61K031-137; A61K045-06
CC 1-9 (Pharmacology)
TI Use of at least one effector of glutathione metabolism, together with α-lipoic acid, for the treatment of chronic obstructive *lung* diseases
ST chronic obstructive *lung* disease treatment lipoate glutathione metab effector; cytoprotection chronic obstructive *lung* disease lipoate glutathione metab effector
IT Drug delivery systems
(aerosols; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive *lung* disease)
IT Macrophage
(alveolar; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive *lung* disease)
IT *Lung*, disease
(chronic obstructive *pulmonary* disease; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive *lung* disease)
IT Drug delivery systems
(emulsions; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive *lung* disease)
IT Combination chemotherapy
Cytoprotective agents
Drug interactions
Human
Metabolism
Phagocytosis
(glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive *lung* disease)
IT Thiols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive *lung* disease)
IT Drug delivery systems

(granules; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(inhalants; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT ***Lung***
(macrophage; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(oral; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(parenterals; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(powders; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(prodrugs; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(solns.; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(tablets, coated; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT Drug delivery systems
(tablets; glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT 70-18-8, Glutathione, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

IT ***1200-22-2***, α-Lipoic acid 18683-91-5, Ambroxol
22888-70-6, Silibinin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glutathione metabolism effector with α-lipoic acid, for treatment of chronic obstructive ***lung*** disease)

L20 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
INCL 435006000; 435007230; 514321000; 514651000
CC 1-6 (Pharmacology)
Section cross-reference(s): 14
TI Novel pathways in the etiology of cancer, and treatment methods
ST estrogen receptor pos breast cancer NFkappaB activation DNA binding; quinine mediated estrogen receptor activation breast cancer; cancer antitumor hormone therapy

IT Oligonucleotides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((kB site) Decoy; pathways in etiol. of cancer, and treatment methods)

IT Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(52 kDa variant; pathways in etiol. of cancer, and treatment methods)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AP-1 (activator protein 1); pathways in etiol. of cancer, and treatment methods)

IT Proteins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AvrA; pathways in etiol. of cancer, and treatment methods)

IT Complement receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C5a; pathways in etiol. of cancer, and treatment methods)

IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Estrogen enhanced transcript; pathways in etiol. of cancer, and treatment methods)

IT Benincasa
(Fructus Benincasae Recens; pathways in etiol. of cancer, and treatment methods)

IT Polysaccharides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ganodermalucidum; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Glucorticoid-induced leucine zipper protein; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HSCO; pathways in etiol. of cancer, and treatment methods)

IT Heat-shock proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HSP 72; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IkB-like; pathways in etiol. of cancer, and treatment methods)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IκB (inhibitor of NF-κB); pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Kaposi's sarcoma-associated herpesvirus K1; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Leucine-rich effector, Salmonella & Shigella; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Murr1; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NDPP1 (CARD protein); pathways in etiol. of cancer, and treatment methods)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(NF-κB (nuclear factor of κ light chain gene enhancer in B-cells); pathways in etiol. of cancer, and treatment methods)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NLS Cell permeable peptides; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Neurofibromatosis-2 (NF-2); pathways in etiol. of cancer, and treatment methods)

IT Gene, animal
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PTEN; pathways in etiol. of cancer, and treatment methods)

IT Polysaccharides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Protein-bound; pathways in etiol. of cancer, and treatment methods)

IT Natural products, pharmaceutical
RL: BIOL (Biological study); USES (Uses)
(Qingkailing; pathways in etiol. of cancer, and treatment methods)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RelA, RelA peptides (P1 and P6); pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SOCS-1 (suppressor of cytokine signaling-1); pathways in etiol. of cancer, and treatment methods)

IT Surfactant proteins (*pulmonary*)
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SP-A; pathways in etiol. of cancer, and treatment methods)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Sp1; pathways in etiol. of cancer, and treatment methods)

IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Triglyceride-rich lipoproteins; pathways in etiol. of cancer, and treatment methods)

IT Human immunodeficiency virus 1
(Vpu protein; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ZAS3; pathways in etiol. of cancer, and treatment methods)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ZUD; pathways in etiol. of cancer, and treatment methods)

IT Allium sativum
(aged garlic extract; pathways in etiol. of cancer, and treatment methods)

IT Macrolides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotics; pathways in etiol. of cancer, and treatment methods)

IT DNA

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(binding; pathways in etiol. of cancer, and treatment methods)
IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(boronic acid peptides; pathways in etiol. of cancer, and treatment methods)
IT Acids, biological studies
Group IIIA element compounds
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(boronic acids, boronic acid peptides; pathways in etiol. of cancer, and treatment methods)
IT Mammary gland, neoplasm
(estrogen receptor-pos.; pathways in etiol. of cancer, and treatment methods)
IT Ginkgo biloba
Rubus occidentalis
(extract; pathways in etiol. of cancer, and treatment methods)
IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(gene vpu, HIV-1; pathways in etiol. of cancer, and treatment methods)
IT Antigens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(hepatitis C core; pathways in etiol. of cancer, and treatment methods)
IT Natural products, pharmaceutical
RL: BIOL (Biological study); USES (Uses)
(herbal compound 861; pathways in etiol. of cancer, and treatment methods)
IT Osmolarity
(hyperosmolarity; pathways in etiol. of cancer, and treatment methods)
IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(i.v.; pathways in etiol. of cancer, and treatment methods)
IT ADP ribosylation
(inhibitors; pathways in etiol. of cancer, and treatment methods)
IT Diterpenes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(kaurane; pathways in etiol. of cancer, and treatment methods)
IT Sesquiterpenes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(lactones; pathways in etiol. of cancer, and treatment methods)
IT Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(lazaroids; pathways in etiol. of cancer, and treatment methods)
IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(ligand-binding, pertussis toxin binding protein; pathways in etiol. of cancer, and treatment methods)
IT Antibiotics
(macrolide; pathways in etiol. of cancer, and treatment methods)
IT Mammary gland, neoplasm
(metastasis; pathways in etiol. of cancer, and treatment methods)

IT Steroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nuclear; pathways in etiol. of cancer, and treatment methods)
IT Low-density lipoproteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(oxidized; pathways in etiol. of cancer, and treatment methods)
IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(p202a (nterferon inducible protein); pathways in etiol. of cancer, and
treatment methods)
IT Antiestrogens
Antioxidants
Antitumor agents
Apple juice
Cell nucleus
Chromatin
Combination chemotherapy
Ganoderma lucidum
Glossogyne tenuifolia
Human
Hypothermia
Kaempferia pandurata
Myxoma virus
Neoplasm
Ochna macrocalyx
Oxidative stress, biological
Phyllanthus niruri
Physiological saline solutions
Probiotics
Prognosis
Rubiaceae
Signal transduction, biological
Tanacetum larvatum
Uncaria tomentosa
Uncaria tomentosa
Urtica
Urtica dioica
Zingiberaceae
(pathways in etiol. of cancer, and treatment methods)
IT Estrogen receptors
neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathways in etiol. of cancer, and treatment methods)
IT Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pathways in etiol. of cancer, and treatment methods)
IT Estrogens
Fibrates
Gangliosides
Glucocorticoids
Guaianolides
Interleukin 10
Interleukin 11
Interleukin 13
Interleukin 4
Lignans
Metals, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pathways in etiol. of cancer, and treatment methods)

IT Aldehydes, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide aldehydes; pathways in etiol. of cancer, and treatment methods)

IT Dialysis
(peritoneal, commerical peritoneal dialysis solution; pathways in etiol. of cancer, and treatment methods)

IT Toxins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pertussis, pertussis toxin binding protein; pathways in etiol. of cancer, and treatment methods)

IT Fatty acids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., omega-3; pathways in etiol. of cancer, and treatment methods)

IT Phosphorylation, biological
(protein; pathways in etiol. of cancer, and treatment methods)

IT Wine
(red; pathways in etiol. of cancer, and treatment methods)

IT Retinoic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(retinoic acid receptor-related orphan receptor-α; pathways in etiol. of cancer, and treatment methods)

IT Orphan receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retinoic acid receptor-related orphan receptor-α; pathways in etiol. of cancer, and treatment methods)

IT Albumins, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serum, bovine; pathways in etiol. of cancer, and treatment methods)

IT Lipoproteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triglyceride-rich; pathways in etiol. of cancer, and treatment methods)

IT Drug delivery systems
(unit doses; pathways in etiol. of cancer, and treatment methods)

IT Nerve
(vagus, elec. stimulation; pathways in etiol. of cancer, and treatment methods)

IT Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α; pathways in etiol. of cancer, and treatment methods)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; pathways in etiol. of cancer, and treatment methods)

IT Amyloid
Catenins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β-; pathways in etiol. of cancer, and treatment methods)

IT 2885-39-4, E 73

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E 73; pathways in etiol. of cancer, and treatment methods)

IT 67-99-2, Gliotoxin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fungal; pathways in etiol. of cancer, and treatment methods)

IT 243981-51-3, LY 29
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LY 29; pathways in etiol. of cancer, and treatment methods)

IT 142243-02-5, Map kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MAPK pathway; pathways in etiol. of cancer, and treatment methods)

IT 130-95-0, Quinine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; pathways in etiol. of cancer, and treatment methods)

IT 9028-35-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, statins; pathways in etiol. of cancer, and treatment methods)

IT 9001-92-7, Protease 74812-49-0, Ubiquitin ligase 140879-24-9, Proteasome
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; pathways in etiol. of cancer, and treatment methods)

IT 9054-89-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manganese-dependent; pathways in etiol. of cancer, and treatment methods)

IT 7440-70-2, Calcium, biological studies 9032-20-6, NADPH:quinone oxidoreductase 9039-53-6, Urokinase plasminogen activator 137632-07-6, Erk1 kinase 137632-08-7, Erk2 kinase 170347-45-2, Erk5 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathways in etiol. of cancer, and treatment methods)

IT 58-27-5, Menadione 66-76-2, Dicoumarol
RL: PAC (Pharmacological activity); BIOL (Biological study)
(pathways in etiol. of cancer, and treatment methods)

IT 50-02-2, Dexamethasone 50-35-1, Thalidomide 50-78-2, Aspirin 50-81-7, VitaminC, biological studies 52-90-4, L-Cysteine, biological studies 53-03-2, Prednisone 53-96-3, 2-Acetylaminofluorene 54-11-5, Nicotine 54-21-7, Sodium salicylate 55-21-0, Benzamide 55-91-4, Diisopropylfluorophosphate 58-61-7, Adenosine, biological studies 59-02-9, α-Tocopherol 59-05-2, Methotrexate 63-39-8, UTP 66-71-7, 1,10-Phenanthroline 67-42-5, EGTA 67-68-5, Dimethylsulfoxide, biological studies 70-18-8, Glutathione, biological studies 73-31-4, Melatonin 76-75-5, Thiopental 77-52-1, Ursolic acid 79-45-8 80-05-7, Bisphenol A, biological studies 83-43-2, Methylprednisolone 83-79-4, Rotenone 83-86-3, Phytic acid 89-57-6, Mesalamine 97-77-8, Disulfiram 98-92-0, Nicotinamide 103-90-2, Acetaminophen 104-46-1, Anethole 114-07-8, Erythromycin 114-25-0, Biliverdin 117-39-5, Quercetin 120-80-9, Catechol, biological studies 123-31-9, Hydroquinone, biological studies 128-53-0, N-Ethyl-maleimide 147-84-2, biological studies 154-23-4D, Catechol, derivs. 253-82-7D, Quinazoline, derivs. 254-04-6D, 2H-1-Benzopyran, derivs. 322-79-2, Triflusal 362-07-2, 2-Methoxyestradiol 363-24-6, Prostaglandin E2 402-71-1, N-α-Tosyl-L-phenylalaninechloromethylketone 404-86-4, Capsaicin 446-72-0, Genistein 458-37-7, Curcumin 462-20-4, DihydrolipoicAcid 465-16-7, Oleandrin 472-15-1, Betulinic acid

472-61-7, Astaxanthin 475-25-2, Hematein 478-43-3, Rhein 479-98-1, Aucubin 481-49-2, Cepharanthine 483-66-9, Sphondin 491-67-8, Baicalein 491-70-3, Luteolin 497-30-3, Ergothioneine 500-38-9 501-36-0, Resveratrol 518-82-1, Emodin 520-36-5, Apigenin 524-12-9, Wedelolactone 528-43-8, Magnolol 532-11-6 537-40-6, Trilinolein 548-04-9, Hypericin 599-79-1, Sulfasalazine 616-91-1, N-Acetyl-L-cysteine 617-35-6, EthylPyruvate 624-49-7, Dimethylfumarate 630-08-0, Carbon monoxide, biological studies 632-85-9, Wogonin 637-03-6, Phenylarsineoxide 950-99-2 989-51-5, Epigallocatechin-3-gallate 1015-89-0, 6(5H)-Phenanthridinone 1121-30-8, Pyrithione ***1200-22-2***, α-Lipoic acid 1405-86-3, Glycyrrhizin 1406-18-4D, Vitamin E, derivs. 1617-53-4, Amentoflavone 1746-01-6, Dioxin 1948-33-0, tert-Butylhydroquinone 2238-90-6, Psychosine 2257-09-2, Phenethylisothiocyanate 2364-87-6, N-α-Tosyl-L-lysinechloromethylketone 2447-54-3, Sanguinarine 2457-80-9, 5'-Methylthioadenosine 2750-76-7, Rifamide 2756-87-8, Monomethylfumarate 3376-24-7 3483-82-7, N-Benzoyl-L-tyrosine-ethylester 3544-24-9, 3-Aminobenzamide 4433-08-3, Bis-eugenol 4707-32-8, β-Lapachone 5104-49-4, Flurbiprofen 5957-80-2, Carnosol 6493-05-6, Pentoxifylline 6736-85-2, Catalposide 6740-88-1, Ketamine 7439-92-1, Lead, biological studies 7439-97-6, Mercury, biological studies 7440-32-6, Titanium, biological studies 7440-38-2, Arsenic, biological studies 7440-43-9, Cadmium, biological studies 7440-47-3, Chromium, biological studies 7440-57-5, Gold, biological studies 7440-66-6, Zinc, biological studies 9000-94-6, Anti-thrombin III 9002-61-3, Chorionic gonadotropin 9005-27-0, Hydroxyethyl starch 9012-76-4, Chitosan 9023-64-7, γ-Glutamylcysteine synthetase 10083-24-6, Piceatannol 10102-43-9, Nitric Oxide, biological studies 10465-78-8, Diamide 10540-29-1, Tamoxifen 10599-90-3, Monochloramine 13292-46-1, Rifampicin 14152-28-4, Prostaglandin A1 14197-60-5 14380-61-1, Hypochlorite 14937-32-7 15687-27-1, Ibuprofen 16330-92-0 17466-45-4, Phalloidin 19542-67-7 19545-26-7, Wortmannin 20554-84-1, Parthenolide 20554-84-1D, Parthenolide, analogs 20874-31-1, N-Acetyl-DL-phenylalanine-β-naphthylester 21593-77-1, S-Allyl-cysteine 22144-77-0, Cytochalasin D 22457-89-2, Benfotiamine ***22888-70-6***, Silibinin 23155-02-4, Fosfomycin 25013-16-5, Butylatedhydroxyanisole 25769-03-3, PDTC 26093-31-2, 7-Amino-4-methylcoumarin 29031-19-4, Glucosamine sulfate 30516-87-1, Azidothymidine 30562-34-6, Geldanamycin 30827-99-7, Pefabloc 32222-06-3, Calcitriol 36791-04-5, Ribavirin 37213-49-3, α-Melanocyte-stimulating hormone 37221-79-7, Vasoactive intestinal peptide 38194-50-2, Sulindac 38748-32-2, Triptolide 42461-84-7, Flunixin meglumine 51050-59-0, 3,4-Dichloroisocoumarin 53179-13-8, Pirfenidone 53902-12-8, Tranilast 54999-07-4, Ergolide 56092-81-0, Ionomycin 56974-61-9, Gabexate mesilate 57444-62-9, Resiniferatoxin 59865-13-3, Cyclosporin A 60719-84-8, Amrinone 60940-34-3, Ebselen 61413-54-5, Rolipram 62645-28-7, Ro106-9920 62996-74-1, Staurosporine 63968-64-9, Artemisinin 65404-34-4, Nitrosylcobalamin 65666-07-1, Silymarin 67526-95-8, Thapsigargin 68573-24-0, N-(p-Coumaroyl) serotonin 70563-58-5, Herbimycin A 72956-09-3, Carvedilol 73981-34-7, Kamebakaurin 75330-75-5, Mevinolin 75747-14-7, 17-Allylamino-17-demethoxygeldanamycin 75899-68-2, 4-Hydroxynonenal 75919-65-2, Calagualine 78954-23-1, Yakuchinone A 80651-76-9, Sanggenon C 81103-11-9, Clarithromycin 81840-15-5, Vesnarinone 81840-57-5, Yakuchinone B 82956-11-4, Nafamostat mesilate 83373-60-8, D609 84573-16-0, Rocaglamide 84687-43-4, Astragaloside IV 85637-73-6, Atrial natriuretic peptide 86408-72-2, Ecabet sodium 86853-04-5, Cycloprodigiosin hydrochloride 87081-35-4, Leptomycin B 88497-87-4, Manassantin A 88497-88-5, Manassantin B 89149-10-0, 15-Deoxyspergualin 89344-48-9, Nacystelyn 89837-52-5, Panduratin A

90098-04-7, Rebamipide 93479-97-1, Glimepiride 94421-68-8, Anandamide
96893-55-9 97322-87-7, Troglitazone 100827-28-9, Erbstatin
101421-72-1D, 6-Aminoquinazoline, derivs. 103177-37-3, Pranlukast
103475-41-8, Tepoxalin 103890-78-4, Lacidipine 104594-70-9,
CaffeicAcidPhenethylEster 104987-11-3, FK506 105686-90-6
108605-62-5, A77 1726 108778-82-1, Survanta 109511-58-2, U0126
110044-82-1 110115-07-6 111025-46-8, Pioglitazone 114798-26-4,
Losartan 118409-62-4, Tyrphostin AG-126 122320-05-2, Secretory
leukocyte protease inhibitor 123663-49-0, T-614 125314-64-9, RO31-8220
126026-32-2, Isomallotochromanol 126026-33-3, Isomallotochromene
127061-56-7 127464-60-2, VEGF 128232-14-4, Raxofelast 129200-07-3,
KT-90 129298-91-5, TNP-470 133407-82-6 133407-86-0 134523-00-5,
Atorvastatin 134867-62-2, IRFI042 136164-66-4, E3330 137061-48-4,
Pituitary adenylate cyclase-activating polypeptide 138069-86-0
141467-21-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pathways in etiol. of cancer, and treatment methods)

IT 142741-24-0, Conophylline 146426-40-6, Flavopiridol 152121-47-6,
SB203580 154447-36-6, LY294002 154531-34-7, Heparin-binding epidermal
growth factor-like growth factor 159934-16-4, Cyclolinteinone
170368-04-4, LF15-0195 170569-86-5, SC236 172854-76-1,
Cacospongionolide B 177931-17-8, Sauchinone 179324-69-7, PS-341
186270-49-5, Angiopoietin 1 188025-51-6 193278-35-2 193481-66-2,
Cycloepoxydon 196309-76-9, BAY-117083 198480-55-6 203455-50-9, MOL
294 205687-01-0, Capsiate 209408-71-9, Petrosaspongiolide M
217949-67-2, MX781 245086-31-1, SUN C8079 287194-40-5 290827-63-3
318967-58-7, APC0576 334538-39-5, THI 52 349081-29-4, Jesterone dimer
374933-93-4, PC-SPES 425371-21-7, Epoxyquinol A 547757-23-3, BMS
345541 630096-17-2, Saucerneol D 630096-18-3, Saucerneol E
662166-51-0, AS 602868 770748-72-6, Indirubin-3'-oxime 851119-19-2,
Shuanghuanglian 874742-80-0 874742-81-1 874918-09-9, LY 30
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pathways in etiol. of cancer, and treatment methods)

IT 874932-74-8 874932-75-9 874932-76-0 874932-77-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; novel pathways in the etiol. of cancer,
and treatment methods)

IT 12001-79-5, Vitamin K
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vitamin K cycle; pathways in etiol. of cancer, and treatment methods)

L20 6 ANSWERS USPATFULL
AN 2001:112285 USPATFULL
TI Method of treatment of glutathione deficient mammals
NCL NCLM: 514/002.000
NCLS: 424/049.000; 424/054.000; 424/535.000; 424/655.000; 514/007.000;
514/012.000; 514/021.000; 514/023.000; 514/251.000; 514/276.000;
530/365.000; 530/833.000
IC [7]
ICM A01N037-18
ICS A61K038-02
IPCI A01N0037-18 [ICM,7]; A61K0038-02 [ICS,7]
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A23L0001-302 [I,A];
A23L0001-302 [I,C*]; A23L0001-305 [I,A]; A23L0001-305 [I,C*];
A61K0031-185 [I,C*]; A61K0031-197 [I,A]; A61K0031-375 [I,A];
A61K0031-375 [I,C*]; A61K0031-70 [I,A]; A61K0031-70 [I,C*]
AN 2001:112285 DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L20 6 ANSWERS USPATFULL
AN 2002:243590 USPATFULL
TI Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
NCL NCLM: 514/027.000
NCLS: 514/100.000; 514/406.000; 514/423.000; 514/456.000; 514/460.000; 514/547.000
IC [7]
ICM A61K031-7048
ICS A61K031-665; A61K031-415; A61K031-401; A61K031-366; A61K031-352
IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0031-665 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-401 [ICS,7]; A61K0031-366 [ICS,7]; A61K0031-352 [ICS,7]
IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-51 [I,C*]; A61K0009-51 [I,A]; A61K0031-185 [I,C*]; A61K0031-195 [I,A]; A61K0031-198 [I,A]; A61K0031-21 [I,C*]; A61K0031-22 [I,A]; A61K0031-225 [I,A]; A61K0031-34 [I,C*]; A61K0031-34 [I,A]; A61K0031-35 [I,C*]; A61K0031-35 [I,A]; A61K0031-352 [I,C*]; A61K0031-355 [I,A]; A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-385 [I,C*]; A61K0031-385 [I,A]; A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0033-04 [I,C*]; A61K0033-04 [I,A]; A61K0033-38 [I,C*]; A61K0033-38 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A]; A61K0039-39 [I,C*]; A61K0039-39 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
AN 2002:243590 DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

ALL ANSWERS HAVE BEEN SCANNED

=> d l20 1-6 ibib

L20 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:101964 CAPLUS
DOCUMENT NUMBER: 144:184652
TITLE: Novel pathways in the etiology of cancer, and treatment methods
INVENTOR(S): Benz, Christopher C.
PATENT ASSIGNEE(S): Buck Institute for Age Research, USA
SOURCE: U.S. Pat. Appl. Publ., 49 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006024691	A1	20060202	US 2005-90546		20050324
PRIORITY APPLN. INFO.:			US 2004-556774P	P	20040325
			US 2004-580534P	P	20040616
			US 2004-629691P	P	20041119

L20 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:612080 CAPLUS
DOCUMENT NUMBER: 143:91050
TITLE: Use of at least one effector of glutathione metabolism, together with α-lipoic acid, for the treatment of chronic obstructive ***lung***

diseases

INVENTOR(S): Ansorge, Siegfried; Koegst, Dieter; Tager, Michael; Fries, Gerhard

PATENT ASSIGNEE(S): Esparma G.m.b.H., Germany; IMTM G.m.b.H.

SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063234	A2	20050714	WO 2004-EP14687	20041223
WO 2005063234	A3	20050922		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10360954	B3	20050818	DE 2003-10360954	20031223
EP 1699451	A2	20060913	EP 2004-804278	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 2007212339	A1	20070913	US 2007-584072	20070403
PRIORITY APPLN. INFO.:			DE 2003-10360954 A	20031223
			WO 2004-EP14687 W	20041223

L20 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2007:164861 USPATFULL

TITLE: Method of treating glutathione deficient mammals

INVENTOR(S): Keller, Robert H., Weston, FL, UNITED STATES
Kirchenbaum, David, Weston, FL, UNITED STATES

PATENT ASSIGNEE(S): Vit-Immune, L.C., Hollywood, FL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 39705	E1	20070626	
	US 6262019		20010717	(Original)
APPLICATION INFO.:	US 2001-994164		20011126	(9)
	US 1999-302217		19990429	(Original)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83661P	19980430 (60)

DOCUMENT TYPE: Reissue

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Wax, Robert A.

LEGAL REPRESENTATIVE: Frommer Lawrence & Haug LLP, Santucci, Ronald R.

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 4 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2003:113490 USPATFULL
TITLE: Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
INVENTOR(S): Wilburn, Michael D., Cedar Hill, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078231	A1	20030424
APPLICATION INFO.:	US 2001-886612	A1	20010622 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2002:243590 USPATFULL
TITLE: Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
INVENTOR(S): Kindness, George, Middletown, OH, UNITED STATES
Schumm, Brooke, III, Ellicott City, MD, UNITED STATES
Guilford, F. Timothy, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132781	A1	20020919
APPLICATION INFO.:	US 2001-997490	A1	20011117 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-912703, filed on 25 Jul 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US31328, filed on 6 Oct 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-238505P	20001006 (60)
	US 2000-238506P	20001006 (60)
	US 2000-243901P	20001027 (60)
	US 2000-243902P	20001027 (60)
	US 2000-245592P	20001103 (60)
	US 2001-264511P	20010126 (60)
	US 2001-307689P	20010725 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROOKE SCHUMM, III, DANEKER, MCINTIRE, SCHUMM, PRINCE, GOLDSTEIN, ET A, 210 N CHARLES ST, SUITE 800, BALTIMORE, MD, 21201
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 2328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2001:112285 USPATFULL

TITLE: Method of treatment of glutathione deficient mammals
INVENTOR(S): Keller, Robert H, Weston, FL, United States
Kirshenbaum, David W, Weston, FL, United States
PATENT ASSIGNEE(S): Vit-Immune, L. C., Hollywood, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6262019	B1	20010717
APPLICATION INFO.:	US 1999-302217		19990429 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83661P	19980430 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Tu, Stephen
LEGAL REPRESENTATIVE: Pitney, Hardin, Kipp & Szuch, LLP
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

```
L1  (          2)SEA FILE=REGISTRY ABB=ON  PLU=ON  "LIPOIC ACID"/CN
L2  (          1)SEA FILE=REGISTRY ABB=ON  PLU=ON  SILIBININ/CN
L3  (         15)SEA FILE=CAPLUS ABB=ON  PLU=ON  L1 AND L2
L4  (          0)SEA FILE=MEDLINE ABB=ON  PLU=ON  L1 AND L2
L5  (         13)SEA FILE=USPATFULL ABB=ON  PLU=ON  L1 AND L2
L6  (          0)SEA FILE=USPATOLD ABB=ON  PLU=ON  L1 AND L2
L7  (          1)SEA FILE=USPAT2 ABB=ON  PLU=ON  L1 AND L2
L8  (         29)SEA L1 AND L2
L9  (          1)SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 AND (COPD OR "CHRONIC AIRFLO
L10 (          0)SEA FILE=MEDLINE ABB=ON  PLU=ON  L4 AND (COPD OR "CHRONIC AIRFL
L11 (          0)SEA FILE=USPATFULL ABB=ON  PLU=ON  L5 AND (COPD OR "CHRONIC AIR
L12 (          0)SEA FILE=USPATOLD ABB=ON  PLU=ON  L6 AND (COPD OR "CHRONIC AIRF
L13 (          0)SEA FILE=USPAT2 ABB=ON  PLU=ON  L7 AND (COPD OR "CHRONIC AIRFLO
L14 (          1)SEA L8 AND (COPD OR "CHRONIC AIRFLOW OBSTRUCTION" OR "AIRFLOW O
L15 (          2)SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 AND (LUNG OR RESPIRAT? OR PU
L16 (          0)SEA FILE=MEDLINE ABB=ON  PLU=ON  L4 AND (LUNG OR RESPIRAT? OR P
L17 (          4)SEA FILE=USPATFULL ABB=ON  PLU=ON  L5 AND (LUNG OR RESPIRAT? OR
L18 (          0)SEA FILE=USPATOLD ABB=ON  PLU=ON  L6 AND (LUNG OR RESPIRAT? OR
L19 (          0)SEA FILE=USPAT2 ABB=ON  PLU=ON  L7 AND (LUNG OR RESPIRAT? OR PU
L20 (          6)SEA L8 AND (LUNG OR RESPIRAT? OR PULMONAR?)
```

Query #5 deleted.

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
#28	Search **(#21) AND EMPHYSEMA**	20:12:13	0
#27	Search **(#21) AND (#25)**	20:08:16	0
#26	Search **(copd or "Chronic Airflow Obstruction" or "Airflow Obstruction" or "Chronic Obstructive Airway Disease" or "Chronic Obstructive Lung Disease" or "Chronic Obstructive Pulmonary Disease" or COAD or "CHRONIC BRONCHITIS" or "PULMONARY EMPHYSEMA") AND (#23)**	20:07:26	0
#25	Search **copd or "Chronic Airflow Obstruction" or "Airflow Obstruction" or "Chronic Obstructive Airway Disease" or "Chronic Obstructive Lung Disease" or "Chronic Obstructive Pulmonary Disease" or COAD or "CHRONIC BRONCHITIS" or "PULMONARY EMPHYSEMA"**	20:07:18	41495
#24	Search **(#18) AND (#21) copd**	20:06:28	0
#23	Search **(#18) AND (#21)**	20:06:12	128
#22	Search **((silibinin or sylimarin or silymarin or silybin or silybine or silliver)) AND (#16)**	20:05:24	0
#21	Search **(silibinin or sylimarin or silymarin or silybin or silybine or silliver)**	20:05:01	1131
#20	Search **(silibinin or sylimarin or silymarin) AND (#16)**	20:03:50	0
#19	Search **silibinin or sylimarin or silymarin**	20:03:43	1098
#16	Search **GSH levels copd**	20:03:09	28
#18	Search **Glutathione or (GSH)**	20:02:50	78660
#15	Search **GSH levels** Sort by: **PublicationDate**	18:49:19	7681

Start →

Clear History